OR WAIT 15 SECS
Thermo Fisher Scientific has announced a collaboration that aims to introduce mass spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare.
Thermo Fisher Scientific has announced a collaboration that aims to introduce mass spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare. A collaboration between the company’s Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre; Toshihide Nishimura, professor at the Tokyo Medical University Hospital; and Gyorgy Marko-Varga, professor at the Tokyo Medical University Hospital and Lund University, Sweden, is to establish and support a new Biomarker Research Centre in Tokyo, Japan. The new centre will focus on biomarker discovery and quantification, disease mechanisms, therapeutic drug monitoring and disease pathophysiology.
“In Japan there is an urgent need to develop more targeted disease detection and treatments for a rapidly growing patient population,” said Murray Wigmore, senior director of commercial operations in Japan, Thermo Fisher Scientific. “The Tokyo Biomarker Research Centre will be developed as the model to replicate the excellence of BRIMS in international markets.”
Correlation of protein expression and quantitative regulation for diseases of key concern in Japan, including lung cancer, cardiovascular disease and chronic obstructive pulmonary disease (COPD), will be performed to discover biomarker candidates related to drug response. The research centre will also house an archive with comprehensive tissue and blood sample collections, along with access to complementary clinical and demographic data. The archive will include samples from drug responder and non-responders, and material from clinical studies performed in Scandinavia and other European countries.
For more information visit www.thermoscientific.com/ms